Navigation Links
Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
Date:11/4/2010

e Call InformationA conference call will take place today, Thursday, November 4, 2010, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management. To access the live conference call via phone, dial 800-573-4754 in the U.S. or Canada and 617-224-4325 for international callers. Please specify to the operator that you would like to join the "Genoptix Third Quarter 2010 Earnings Conference Call." The participant code for the call is 96795959. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, November 11, 2010. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77666858.

The conference call will also be webcast live on the "Investors" section of the Genoptix website at www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Thursday, December 2, 2010.

About Genoptix, Inc.Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists, and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 I
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genoptix Ranked 41st Fastest-Growing Company in North America on Deloittes 2010 Technology Fast 500™
2. Genoptix Announces Participation at the 2010 UBS Global Life Sciences Conference
3. Genoptix, Inc. to Announce First Quarter 2010 Financial Results
4. Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results
5. Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference
6. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
7. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
8. Addus HomeCare Reports Third Quarter 2010 Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2010
10. Amylin Pharmaceuticals Reports Third Quarter Financial Results
11. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/11/2014)... The Williams Rejuva Center excited to ... patient’s unique treatment regime. Using the Vectra 3D ... trouble areas can be quickly created. The evaluation ... , Vectra 3D is a cutting-edge computer imaging system. ... a quick ‘snapshot’ of the skin to determine the ...
(Date:7/11/2014)... 11, 2014 Even the hot Texas sun ... Elementary School . The school had previously invested ... equipment from APCPLAY, but recently asked for an innovative ... , Godley Elementary School chose a Rectangular Shade from ... for children on their playground. The shade measures 24’W ...
(Date:7/11/2014)... July 11, 2014 Shu Cosmetic ... perineplasty for each qualifying patient undergoing a ... been performing laser vaginal rejuvenation, an advanced type ... The LVR procedure decreases the internal and external ... muscle tone, strength, and control, resulting in enhanced ...
(Date:7/11/2014)... ASHBURN PSYCHOLOGICAL AND PSYCHIATRIC SERVICES , On July 1st, Senate ... disability or autism to have a special code placed on ... law enforcement or first responders that they are dealing with ... a central Virginia mother, Ms. Pam Mines, who wanted to ... JP. During a news conference after the law passed, ...
(Date:7/10/2014)... (PRWEB) July 11, 2014 Karen Middleton, ... President and CEO of Planned Parenthood of the Rocky ... Senator Mark Udall and Representative Diana DeGette were in ... Court’s Hobby Lobby decision and keeping bosses out of ... representatives listened to the president today in Denver addressing ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 3Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2
... new study show that Aldara (imiquimod) Cream 5 percent, which ... process of premature aging and improve the complexion of the ... improvement in fine lines, wrinkles, dyspigmentations and texture. ... facility presented these findings at the 64th Annual Meeting of ...
... lifting weights, a new study shows. Weight lifting at least ... your waist. In addition, it can ensure a healthy heart ... among nearly 164 obese or overweight women. The study participants ... The experimental group members were required to undertake strength training ...
... When children turn into adults, some genes involved in controlling ... a study of more than 500 pairs of twins. //,Black ... showed that changes in gene expression between ages 14 and ... pressure variation that occurred by age 18. This was told ...
... apnea is a disorder that can contribute to the development ... to 20 million Americans// have obstructive sleep apnea, but most ... risk factor is obesity. Men are twice as likely as ... Sleep Medicine (AASM) said that a treatment called continuous positive ...
... to 12 million suffer from winter depression, of which ... 35 years of age.// ,Current research indicates ... that may cause symptoms such as loss of energy, ... and sleepiness. Individuals affected by "winter depression" who go ...
... group of friends and family frustrated with dieting and weight ... them to lose more than 75 lbs. over a 4 ... to lose over 75 lbs, exercise more than 25 miles, ... original body weight., ,The competition began with Jen sending ...
Cached Medicine News:Health News:Gene alteration observed in children turning into adults 2Health News:'Winter Blues' Treated by Breakthrough Lighting Technology 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: